Trials / Completed
CompletedNCT02975934
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- pharmaand GmbH · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Rucaparib will be administered daily. |
| DRUG | Abiraterone acetate or Enzalutamide or Docetaxel | Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks. |
Timeline
- Start date
- 2017-06-13
- Primary completion
- 2022-08-25
- Completion
- 2024-08-08
- First posted
- 2016-11-29
- Last updated
- 2025-07-25
- Results posted
- 2023-08-16
Locations
150 sites across 12 countries: United States, Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02975934. Inclusion in this directory is not an endorsement.